Litcius/Paper detail

Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-κB activity via UHRF1/DNMT1 complex

Shuye Lin, Hongyun Ruan, Lin Qin, Cong Zhao, Meng Gu, Ziyu Wang, Bin Liu, Haichao Wang, Jinghui Wang

2023International Journal of Biological Sciences27 citationsDOIOpen Access PDF

Abstract

results also showed that DNMT1 inhibitor (5-Aza) in combination with gefitinib/osimertinib restored sensitivity to OR/GR cells. Acquired drug resistance of gefitinib/osimertinib promoted UHRF1/DNMT1 complex to inhibit the expression of MUC17. MUC17 in GR/OR cells may act as an epigenetic sensor for biomonitoring the resistance to EGFR-TKIs.

Topics & Concepts

GefitinibDNMT1OsimertinibCancer researchEpidermal growth factor receptorDNA methylationDownregulation and upregulationEpigeneticsMethyltransferaseBiologyMethylationCancerErlotinibGene expressionBiochemistryGeneticsGeneRNA modifications and cancerLung Cancer Treatments and MutationsEpigenetics and DNA Methylation
Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-κB activity via UHRF1/DNMT1 complex | Litcius